Skip to main content
Top
Published in: Forensic Science, Medicine and Pathology 1/2019

01-03-2019 | Case Report

Fatal combination of mitragynine and quetiapine – a case report with discussion of a potential herb-drug interaction

Author: Rhome L. Hughes

Published in: Forensic Science, Medicine and Pathology | Issue 1/2019

Login to get access

Abstract

Kratom is a plant with dose-dependent mixed stimulant and opioid properties whose pharmacologic characteristics and social impact continue to be described. The main active isolate of kratom is mitragynine, an indole-containing alkaloid with opioid-like effects. Kratom toxicity and kratom-associated fatalities have been described, including those in association with additional drugs. In this paper we describe the case of a 27-year-old man who was found deceased with a toxic blood concentration of quetiapine in conjunction with the qualitative presence of mitragynine. Investigative and autopsy findings suggested perimortem hyperthermia and seizure-like activity. Kratom toxicity and kratom-associated fatalities are being increasingly reported. Experiments with kratom extracts have shown inhibitory effects upon hepatic CYP enzymes, leading to previous speculation of the potential for clinically significant interactions between kratom and a wide array of medications. Herein is described a fatal case of quetiapine toxicity complicated by mitragynine use. The potential ability of mitragynine to alter the pharmacokinetics of a prescription medication via inhibition of its hepatic metabolism is discussed.
Literature
1.
go back to reference Trakulsrichai S, Sathirakul K, Auparakkitanon S, Krongvorakul J, Sueajai J, Noumjad N, et al. Pharmacokinetics of mitragynine in man. Drug Des Devel Ther. 2015;9:2421–9.PubMedPubMedCentral Trakulsrichai S, Sathirakul K, Auparakkitanon S, Krongvorakul J, Sueajai J, Noumjad N, et al. Pharmacokinetics of mitragynine in man. Drug Des Devel Ther. 2015;9:2421–9.PubMedPubMedCentral
2.
go back to reference Prozialeck W, Jivan J, Andurkar S. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112:792–9.PubMed Prozialeck W, Jivan J, Andurkar S. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112:792–9.PubMed
3.
go back to reference Pantano F, Tittarelli R, Mannocchi G, Zaami S, Ricci S, Giorgetti R, et al. Hepatotoxicity induced by “the 3Ks”: kava, kratom and khat. Int J Mol Sci. 2016;17:580.CrossRef Pantano F, Tittarelli R, Mannocchi G, Zaami S, Ricci S, Giorgetti R, et al. Hepatotoxicity induced by “the 3Ks”: kava, kratom and khat. Int J Mol Sci. 2016;17:580.CrossRef
5.
go back to reference Castillo A, Payne JD, Nugent K. Posterior reversible leukoencephalopathy syndrome after kratom ingestion. Proc (Baylor Univ Med Cent). 2017;30:355–7.CrossRef Castillo A, Payne JD, Nugent K. Posterior reversible leukoencephalopathy syndrome after kratom ingestion. Proc (Baylor Univ Med Cent). 2017;30:355–7.CrossRef
6.
go back to reference Galbis-Reig D. A case report of kratom addiction and withdrawal. WMJ. 2016;115:49–52.PubMed Galbis-Reig D. A case report of kratom addiction and withdrawal. WMJ. 2016;115:49–52.PubMed
8.
go back to reference Aggarwal G, Robertson E, McKinlay J, Walter E. Death from kratom toxicity and the possible role of intralipid. J Intensive Care Soc. 2018;19:61–3.CrossRef Aggarwal G, Robertson E, McKinlay J, Walter E. Death from kratom toxicity and the possible role of intralipid. J Intensive Care Soc. 2018;19:61–3.CrossRef
9.
go back to reference Domingo O, Roider G, Stover A, Graw M, Musshoff F, Sachs H, et al. Mitragynine concentrations in two fatalities. Forensic Sci Int. 2017;271:e1–7.CrossRef Domingo O, Roider G, Stover A, Graw M, Musshoff F, Sachs H, et al. Mitragynine concentrations in two fatalities. Forensic Sci Int. 2017;271:e1–7.CrossRef
10.
go back to reference Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med. 2016;130:127–38.CrossRef Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med. 2016;130:127–38.CrossRef
11.
go back to reference Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following kratom (mitragynine speciosa korth) exposure. J Med Toxicol. 2010;6:424–6.CrossRef Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following kratom (mitragynine speciosa korth) exposure. J Med Toxicol. 2010;6:424–6.CrossRef
12.
go back to reference Baselt RC. Disposition of toxic drugs and chemicals in man. 8th ed. Foster City (CA): Biomedical Publications; 2008. Baselt RC. Disposition of toxic drugs and chemicals in man. 8th ed. Foster City (CA): Biomedical Publications; 2008.
13.
go back to reference Molina DK. Handbook of forensic toxicology for medical examiners. Boca Raton: CRC Press; 2010. Molina DK. Handbook of forensic toxicology for medical examiners. Boca Raton: CRC Press; 2010.
14.
go back to reference Gortney JS, Fagan A, Kissack JC. Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother. 2009;43:785–91.CrossRef Gortney JS, Fagan A, Kissack JC. Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother. 2009;43:785–91.CrossRef
15.
go back to reference Raffa RB. Kratom and other mitragynines: the chemistry and pharmacology of opioids from a non-opium source. Boca Raton: CRC Press; 2015. Raffa RB. Kratom and other mitragynines: the chemistry and pharmacology of opioids from a non-opium source. Boca Raton: CRC Press; 2015.
16.
go back to reference Harmon TJ, Benitez JG, Krenzelok EP, Cortes-Belen E. Loss of consciousness from acute quetiapine overdosage. J Toxicol Clin Toxicol. 1998;36:599–602.CrossRef Harmon TJ, Benitez JG, Krenzelok EP, Cortes-Belen E. Loss of consciousness from acute quetiapine overdosage. J Toxicol Clin Toxicol. 1998;36:599–602.CrossRef
17.
go back to reference Devane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40:509–22.CrossRef Devane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40:509–22.CrossRef
18.
go back to reference Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, Hermann M. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos. 2009;37:254–8.CrossRef Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, Hermann M. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos. 2009;37:254–8.CrossRef
19.
go back to reference Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61:58–69.CrossRef Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61:58–69.CrossRef
20.
go back to reference Hanapi NA, Ismail S, Mansor SM. Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities. Pharm Res. 2013;5:241–6. Hanapi NA, Ismail S, Mansor SM. Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities. Pharm Res. 2013;5:241–6.
21.
go back to reference Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391–6.PubMed Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391–6.PubMed
22.
go back to reference Hasselstrom J, Linnet K. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions. Drug Metabol Drug Interact. 2006;21:187–211.CrossRef Hasselstrom J, Linnet K. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions. Drug Metabol Drug Interact. 2006;21:187–211.CrossRef
23.
go back to reference Meyer MR, Wagmann L, Schneider-Daum N, Loretz B, de Souza Carvalho C, Lehr CM, et al. P-glycoprotein interactions of novel psychoactive substances – stimulation of ATP consumption and transport across Caco-2 monolayers. Biochem Pharmacol. 2015;94:220–6.CrossRef Meyer MR, Wagmann L, Schneider-Daum N, Loretz B, de Souza Carvalho C, Lehr CM, et al. P-glycoprotein interactions of novel psychoactive substances – stimulation of ATP consumption and transport across Caco-2 monolayers. Biochem Pharmacol. 2015;94:220–6.CrossRef
24.
go back to reference Schmitt U, Kirschbaum KM, Poller B, Kusch-Poddar M, Drewe J, Hiemke C, et al. In vitro p-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. Pharmacol Biochem Behav. 2012;102:312–20.CrossRef Schmitt U, Kirschbaum KM, Poller B, Kusch-Poddar M, Drewe J, Hiemke C, et al. In vitro p-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. Pharmacol Biochem Behav. 2012;102:312–20.CrossRef
Metadata
Title
Fatal combination of mitragynine and quetiapine – a case report with discussion of a potential herb-drug interaction
Author
Rhome L. Hughes
Publication date
01-03-2019
Publisher
Springer US
Published in
Forensic Science, Medicine and Pathology / Issue 1/2019
Print ISSN: 1547-769X
Electronic ISSN: 1556-2891
DOI
https://doi.org/10.1007/s12024-018-0049-9

Other articles of this Issue 1/2019

Forensic Science, Medicine and Pathology 1/2019 Go to the issue